(2020-04-22) Akili Announces Endeavor Digital Attention Treatment Is Now Available For Children With Add

Akili Announces Announces Endeavor™ Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) (ADD) under FDA’s COVID-19 Enforcement Discretion Guidance. Delivered through a captivating video game experience, ENDEAVOR is a digital treatment that has been shown in a rigorously designed and conducted clinical research program to improve attention function, as measured by computer-based testing, in children ages 8-12 years old with primarily inattentive or combined-type ADHD who have a demonstrated attention issue. Attention impairments are a component of ADHD in more than 85% of children diagnosed and can significantly impact daily functioning. (cf (2020-04-14) Covid19 Digital Health Devices For Psychiatric Disorders Policy)

It affects making and keeping friends, completing tasks, building confidence and succeeding in school

avoiding obstacles and collecting targets

The current release of ENDEAVOR is enabled by new guidance from FDA in response to the COVID-19 public health emergency.